XEPLION<sup>®</sup> Aqueous Suspension for IM Injection

DOI Web Site 1 Citations 8 References
  • Wakamatsu Akihide
    Medical Affairs Div., Medical Strategy Dept. Janssen Pharmaceutical K.K.
  • Soga Osamu
    Research & Development Div., CMC Planning Dept. Janssen Pharmaceutical K.K.

Bibliographic Information

Other Title
  • 持効性抗精神病剤 ゼプリオン<sup>®</sup>水懸筋注
  • XEPLION<sup>&reg;</sup> Aqueous Suspension for IM Injection

Search this article

Description

Paliperidone palmitate long-acting injection (Xeplion® aqueous suspension for IM injection, PP) is the long-acting injectable antipsychotic for schizophrenia, which approved in Japan on September 2013. PP is provided as prefilled syringe, which makes enable the injection without preparation just before injection. PP is injected as 150mg at Day 1 and 100mg at Day 8 to deltoid muscles, followed by the injection of 75 mg every 4 week to deltoid or gluteal muscle (appropriately increase or decrease within 25-150mg by depending on the state of patients), indicates the effect on schizophrenia without concomitant oral antipsychotics. In this paper, it is introduced as the characteristics of drug formulation and pharmacokinetics of PP.

Journal

  • Drug Delivery System

    Drug Delivery System 31 (5), 469-475, 2016

    THE JAPAN SOCIETY OF DRUG DELIVERY SYSTEM

Citations (1)*help

See more

References(8)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top